Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aradigm has received the $4m milestone payment from Zogenix based upon the first commercial sale in the US of Sumavel DosePro (sumatriptan injection) needle-free delivery system. The company will receive quarterly royalty payments on all Sumavel DosePro sales.
Subscribe to our email newsletter
Reportedly, in 2006, Aradigm has sold all assets related to the Intraject needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.
Earlier, in July 2009, the FDA has approved Sumavel DosePro for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headaches. Sumavel DosePro delivers subcutaneous (under the skin) sumatriptan, a treatment that provides migraine relief, in a first-of-its-kind needle-free delivery system.
Igor Gonda, president and CEO of Aradigm, said: “The receipt of this milestone reflects our strategy to raise non-dilutive capital by monetizing non-strategic assets. We are pleased with the first commercial sale of this product utilizing technology developed at Aradigm.”
Zogenix and Astellas Pharma (Astellas) have an exclusive co-promotion agreement to market Sumavel DosePro needle-free delivery system in the US. Zogenix is focusing its sales activities primarily on the neurology market while Astellas is focusing principally on primary care physicians.